Clinical news:

Phase II

Here are your up-to-date news results!
Some of these news summaries can show a Published date which makes the news snippet look really dated. This concerns especially study status messages.
Please keep in mind that for studies specifically, the Published date does not represent the date this news was published, but the date the study was started.
If it is shown in this feed, it means that we detected that the status of, or information about that study was changed in the last 14 days.

Clicking the title of the article will give you the original publication.
You can share an article quickly with colleagues via Twitter and LinkedIn!


A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis.
Published:

EudraCT Number: 2018-004258-77
Sponsor Protocol Number: CM-101-PSC-001
Sponsor Name: ChemomAb Ltd.
Start Date: 2019-02-05
Medical condition: Treatment of Primary Sclerosing Cholangitis
Disease:
Version: 20.1
SOC Term: 100000004871
Classification Code: 10036732
Term: Primary sclerosing cholangitis
Level: LLT

Population Age: Adults, Elderly
Gender: Male, Female
Trial Protocol: GB (Prematurely Ended)

A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma ...
Published:

EudraCT Number: 2017-000708-10
Sponsor Protocol Number: CPZP034A2410
Sponsor Name: Novartis Pharma AG
Start Date: 2017-09-18
Medical condition: Advanced and/or metastatic renal cell carcinoma
Disease:
Version: 20.0
SOC Term: 100000004864
Classification Code: 10068208
Term: Renal neoplasms malignant
Level: HLT

Population Age: Adults, Elderly
Gender: Male, Female
Trial Protocol: CZ (Ongoing), DE (Temporarily Halted), ES (Ongoing), AT (Ongoing), GB (Ongoing), HU (Ongoing)

Open label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in previous dupilumab asthma clinical study
Published:

EudraCT Number: 2013-003856-19
Sponsor Protocol Number: LTS12551
Sponsor Name: Sanofi-aventis recherche et développement
Start Date: 2014-05-28
Medical condition: Asthma
Disease:
Version: 16.1
SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders
Classification Code: 10003553
Term: Asthma
Level: PT

Population Age: Adults, Elderly
Gender: Male, Female
Trial Protocol: ES (Completed), IT (Ongoing), PL (Ongoing), DE (Completed), GB (Completed), NL (Completed), HU (Completed), BE (Completed), DK (Completed), SE (Completed), Outside EU/EEA

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
Published: 5 Dec 2019 | 17:00 UTC

Condition:   Breast Cancer
Interventions:   Drug: Avelumab;   Drug: Aspirin;   Drug: Lansoprazole
Sponsors:   The Christie NHS Foundation Trust;   University of Manchester
Not yet recruiting

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Published: 5 Dec 2019 | 17:00 UTC

Condition:   Metastatic or Unresectable Melanoma
Interventions:   Drug: Nivolumab;   Drug: Talazoparib
Sponsor:   Pauline Funchain
Not yet recruiting

A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen
Published: 5 Dec 2019 | 17:00 UTC

Condition:   Asthma
Interventions:   Drug: AZD8154 nebulizer suspension, 20 mg/mL;   Drug: Placebo
Sponsors:   AstraZeneca;   Parexel
Not yet recruiting

A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen
Published: 5 Dec 2019 | 17:00 UTC

Condition:   Asthma
Interventions:   Drug: AZD8154 nebulizer suspension, 20 mg/mL;   Drug: Placebo
Sponsors:   AstraZeneca;   Parexel
Not yet recruiting

Reducing Knee Compression When Sleeping in Those With Knee OA
Published: 5 Dec 2019 | 17:00 UTC

Condition:   Osteoarthritis, Knee
Interventions:   Behavioral: Change in sleeping position;   Behavioral: No change in sleeping position
Sponsor:   University of Bradford
Completed

Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
Published: 5 Dec 2019 | 0:00 UTC

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2 clinical study of its novel NMDA receptor modulator, NYX-458, for the treatment of mild cognitive impairment associated with Parkinson’s disease.

American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
Published: 5 Dec 2019 | 0:00 UTC

PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder

Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder
Published: 5 Dec 2019 | 0:00 UTC

Results from initial 6-patient cohort show pozelimab reduced lactate dehydrogenase (LDH) to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria (PNH), utilizing a weekly subcutaneous dosing regimen

Simvastatin in Uveitis
Published: 3 Dec 2019 | 17:00 UTC

Condition:   Uveitis
Intervention:   Drug: Simvastatin 40mg
Sponsor:   Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology
Completed

Pharmacokinetics of Advantage Anti-Caries Varnish
Published: 3 Dec 2019 | 17:00 UTC

Condition:   Dental Caries
Intervention:   Drug: Anti-caries varnish
Sponsors:   Advantage Silver Dental Arrest, LLC;   University of Washington
Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
Published: 11 Nov 2019 | 17:00 UTC

Condition:   Schizophrenia
Interventions:   Drug: CTP-692;   Drug: Placebo
Sponsors:   Concert Pharmaceuticals;   Cognitive Research Corporation
Recruiting

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
Published: 17 Jul 2019 | 16:00 UTC

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Azacitidine;   Drug: Cusatuzumab
Sponsors:   Janssen Research & Development, LLC;   argenx BVBA
Recruiting

Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Published: 3 May 2019 | 16:00 UTC

Conditions:   Breast Cancer;   DCIS;   LCIS
Intervention:   Radiation: MRIdian Radiation Treatment Unit
Sponsor:   University of Wisconsin, Madison
Suspended

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Published: 27 Mar 2019 | 16:00 UTC

Conditions:   Advanced Digestive System Neuroendocrine Neoplasm;   Digestive System Neuroendocrine Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;   Metastatic Digestive System Neuroendocrine Neoplasm;   Midgut Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor;   Refractory Digestive System Neuroendocrine Neoplasm
Intervention:   Drug: Abemaciclib
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Suspended

Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
Published: 20 Mar 2019 | 16:00 UTC

Condition:   Bone Pain
Interventions:   Drug: Loratadine;   Drug: Placebo
Sponsor:   University of Michigan
Terminated

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
Published: 3 Oct 2018 | 16:00 UTC

Condition:   Urticaria
Intervention:   Drug: Fenebrutinib
Sponsor:   Genentech, Inc.
Terminated

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
Published: 20 Aug 2018 | 16:00 UTC

Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
Interventions:   Drug: SPN-810;   Drug: Placebo
Sponsor:   Supernus Pharmaceuticals, Inc.
Terminated

Echinacea Angustifolia (AnxioCalm) in Anxiety
Published: 13 Mar 2018 | 16:00 UTC

Condition:   Generalized Anxiety Disorder
Interventions:   Dietary Supplement: Echinacea angustifolia;   Dietary Supplement: Placebo
Sponsors:   EuroPharma, Inc.;   Simon Khechinashvili University
Suspended

Intrathecal Paracetamol Before Spinal Anaesthesia With Chloroprocaine HCl 1% for Short Knee Procedures
Published: 9 Feb 2018 | 17:00 UTC

Condition:   Pain, Postoperative
Interventions:   Drug: 30 mg Paracetamol 3% (1 mL);   Drug: 60 mg Paracetamol 3% (2 mL);   Drug: 90 mg Paracetamol 3% (3 mL);   Drug: Placebo, 0.9% saline solution;   Drug: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection
Sponsors:   Sintetica SA;   Cross Research S.A.
Completed

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
Published: 18 Aug 2016 | 16:00 UTC

Condition:   Primary Ciliary Dyskinesia
Interventions:   Drug: VX-371;   Drug: Hypertonic Saline;   Drug: Placebo (0.17% saline);   Drug: Ivacaftor
Sponsors:   Vertex Pharmaceuticals Incorporated;   Parion Sciences
Completed

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Published: 19 Mar 2015 | 16:00 UTC

Condition:   Carcinoma, Non-small-Cell Lung
Interventions:   Drug: Necitumumab;   Drug: Nab-Paclitaxel;   Drug: Carboplatin
Sponsors:   Eli Lilly and Company;   Celgene
Completed



Please note that GR Consulting can not alter or influence the messages displayed, nor is it responsible for its content. If needed or desired, please refer to the original message and/or its originator.